Internal Medicine, Hematology & Oncology · Jonesboro, AR
NPI
1659323608
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
300 Carson St
Jonesboro, AR, 72401
Phone (870) 932-5296
Groups this clinician bills Medicare through
Medicare paid, 2024
$164K
3,114 services
Medicare patients, 2024
598
Average age 74
Drug cost, 2024
$8.1M
2,227 prescriptions
Company payments, 2025
$2,928
From 43 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mazen Khalil was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 1,013 times for 380 patients. In total Mazen Khalil billed 3,114 services in 10 codes, and Medicare paid $164K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-10-24.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 1,013 | 380 | $11.76 | $12K |
| 99214 Office E&M - Established | Facility | 679 | 343 | $65.43 | $44K |
| 99215 Office E&M - Established | Facility | 594 | 193 | $100.16 | $59K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 256 | 101 | $11.77 | $3,014 |
| 99214 Office E&M - Established | Office | 204 | 97 | $63.45 | $13K |
| 99215 Office E&M - Established | Office | 115 | 40 | $99.46 | $11K |
| 99213 Office E&M - Established | Facility | 83 | 62 | $41.35 | $3,432 |
| 99205 Office E&M - New | Facility | 71 | 71 | $126.15 | $8,957 |
| 99213 Office E&M - Established | Office | 25 | 23 | $43.70 | $1,093 |
| 99223 Hospital E&M - Initial | Facility | 24 | 24 | $125.21 | $3,005 |
| 99204 Office E&M - New | Facility | 23 | 23 | $91.51 | $2,105 |
By year: 2022 $142K for 2,273 services; 2023 $130K for 1,814 services; 2024 $164K for 3,114 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mazen Khalil prescribed most often to Medicare patients was Letrozole, with 300 prescriptions and refills. In total Mazen Khalil wrote 2,227 Medicare prescriptions that cost $8.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 300 | 499 | 83 | $5,083 |
| Prochlorperazine Maleate Generic | 109 | 109 | 73 | $1,643 |
| Gabapentin Generic | 108 | 118 | 28 | $667 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 88 | 88 | 36 | $2,001 |
| Tamoxifen Citrate Generic | 87 | 160 | 27 | $1,887 |
| Ondansetron Odt Ondansetron | 85 | 85 | 57 | $1,877 |
| Prednisone Generic | 79 | 95 | 27 | $511 |
| Abiraterone Acetate Generic | 70 | 76 | Under 11 | $234K |
| Hydroxyurea Generic | 66 | 84 | 16 | $1,445 |
| Dexamethasone Generic | 53 | 61 | 38 | $857 |
| Verzenio Abemaciclib | 45 | 45 | Under 11 | $685K |
| Potassium Chloride Generic | 44 | 57 | 23 | $387 |
| Imbruvica Ibrutinib | 43 | 43 | Under 11 | $693K |
| Xtandi Enzalutamide | 38 | 38 | Under 11 | $513K |
| Pantoprazole Sodium Generic | 35 | 54 | 13 | $134 |
Brand drugs: - claims; generic drugs: 1,668 claims; opioid claims: 187.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mazen Khalil $2,928 ($2,928 in general payments such as food, travel and fees) from 43 companies. The largest payer was Pfizer Inc. with $276.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 19 | $276 |
| Novartis Pharmaceuticals Corporation NVS | 17 | $234 |
| Merck Sharp & Dohme LLC MRK | 12 | $230 |
| Janssen Biotech, Inc. JNJ | 11 | $226 |
| Regeneron Healthcare Solutions, Inc. REGN | 4 | $164 |
| AstraZeneca Pharmaceuticals LP AZN | 9 | $151 |
| Abbvie Inc. ABBV | 8 | $142 |
| Daiichi Sankyo Inc. 4568.T | 5 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 4 | $93.63 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 4 | $90.12 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.